Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D-2/D-3 Receptor Antagonist: Phase I Single- and Multiple-Ascending Dose Studies in Healthy Japanese Participants

Yamaguchi, T; Kudou, K; Okamoto, H; Chen, CL; Whiting, R; Sekino, H

Yamaguchi, T (通讯作者)，Takeda Pharmaceut Co Ltd, Takeda Dev Ctr Japan, Chuo Ku, 1-1,Doshomachi 4 Chome, Osaka, Japan.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022; 11 (6): 695

Abstract

Trazpiroben (TAK-906) is a peripherally selective dopamine D-2/D-3 receptor antagonist being developed to treat chronic gastroparesis. This phase I, r......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索